JO3246B1 - اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري - Google Patents

اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري

Info

Publication number
JO3246B1
JO3246B1 JOP/2010/0293A JOP20100293A JO3246B1 JO 3246 B1 JO3246 B1 JO 3246B1 JO P20100293 A JOP20100293 A JO P20100293A JO 3246 B1 JO3246 B1 JO 3246B1
Authority
JO
Jordan
Prior art keywords
protease
human
antibodies
high affinity
activated receptor
Prior art date
Application number
JOP/2010/0293A
Other languages
English (en)
Inventor
J Murphy Andrew
R Salzler Robert
Macdonald Lynn
R Morra Marc
L Lacroix-Fralish Michael
J Papadopoulos Nicholas
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3246B1 publication Critical patent/JO3246B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتعلق الاختراع بتوفير اجسام مضادة ترتبط بمستقبل منشط 2- للبروتياز ( PAR-2) وطرق لاستخدامه . وطبقاً لنماذج معينة من الاختراع تكون الأجسام المضادة عبارة عن اجسام مضادة بشرية كاملة ترتبط ب PAR-2 البشري. تكون الجسام المضادة للاختراع مفيدة من بين أشياء أخرى، في معالجة الأمراض والاضطرابات المرتبطة بواحد او أكثر من الأنشطة البيولوجية ل PAR-2 ، بما في ذلك معالجة حالات الألم والحالات الالتهابية وحالات المعدة والامعاء.
JOP/2010/0293A 2009-09-09 2010-08-23 اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري JO3246B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24078309P 2009-09-09 2009-09-09
US24282109P 2009-09-16 2009-09-16
US31783910P 2010-03-26 2010-03-26

Publications (1)

Publication Number Publication Date
JO3246B1 true JO3246B1 (ar) 2018-03-08

Family

ID=43063654

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0293A JO3246B1 (ar) 2009-09-09 2010-08-23 اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري

Country Status (29)

Country Link
US (3) US8101724B2 (ar)
EP (1) EP2475684B1 (ar)
JP (2) JP5832435B2 (ar)
KR (1) KR101766701B1 (ar)
CN (1) CN102574923B (ar)
AR (1) AR078346A1 (ar)
AU (1) AU2010292342C1 (ar)
BR (1) BR112012005338A2 (ar)
CA (1) CA2773541A1 (ar)
CY (1) CY1118714T1 (ar)
DK (1) DK2475684T3 (ar)
ES (1) ES2609780T3 (ar)
HR (1) HRP20170324T1 (ar)
HU (1) HUE031725T2 (ar)
IL (1) IL218501A (ar)
JO (1) JO3246B1 (ar)
LT (1) LT2475684T (ar)
MX (1) MX2012002927A (ar)
MY (1) MY159551A (ar)
NZ (1) NZ599204A (ar)
PL (1) PL2475684T3 (ar)
PT (1) PT2475684T (ar)
SG (1) SG178976A1 (ar)
SI (1) SI2475684T1 (ar)
SM (2) SMT201700102T1 (ar)
TW (1) TWI492757B (ar)
UY (1) UY32883A (ar)
WO (1) WO2011031695A1 (ar)
ZA (1) ZA201201730B (ar)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
MX359070B (es) 2010-12-01 2018-09-13 Alderbio Holdings Llc Composiciones anti-ngf y uso de las mismas.
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US8987422B2 (en) 2011-09-22 2015-03-24 Amgen Inc. CD27L antigen binding proteins
EP3049418A1 (en) 2013-09-25 2016-08-03 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the par-2 signaling pathway
WO2015128846A1 (en) * 2014-02-28 2015-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region
WO2017023780A1 (en) 2015-07-31 2017-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates for targeting cd56-positive tumors
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
EP3374386B1 (en) 2015-11-13 2024-05-29 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators
CN110312523B (zh) 2016-11-08 2024-04-26 齐鲁皮吉特湾生物治疗有限公司 抗pd1和抗ctla4抗体
IL269134B2 (en) * 2017-03-16 2024-07-01 Medimmune Ltd Antibodies against PAR2 and their use
SG11202107708XA (en) * 2019-01-18 2021-08-30 Janssen Biotech Inc Gprc5d chimeric antigen receptors and cells expressing the same
EP3946332A1 (en) 2019-04-05 2022-02-09 Université de Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
JP7266117B2 (ja) * 2019-05-30 2023-04-27 山東博安生物技術股▲ふん▼有限公司 クローディン１８．２を標的とする抗体又はキメラ抗原受容体
JP7263538B2 (ja) * 2019-11-01 2023-04-24 株式会社 資生堂 皮膚での活性型ｐａｒ－２を指標とした皮膚状態評価方法、ｐａｒ－２活性化促進剤又は抑制剤のスクリーニング方法及びｐａｒ－２活性化抑制剤
CN113248611B (zh) * 2020-02-13 2026-02-06 上海泰槿生物技术有限公司 抗bcma抗体、其药物组合物及应用
CA3173205A1 (en) * 2020-03-31 2021-10-07 Roland B. WALTER Human anti-cd33 antibodies and uses thereof
WO2022040345A1 (en) * 2020-08-18 2022-02-24 Cephalon, Inc. Anti-par-2 antibodies and methods of use thereof
WO2023034560A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting cd33 and uses thereof
JP2024533162A (ja) * 2021-09-02 2024-09-12 メモリアル スローン ケタリング キャンサー センター 抗ｃｄ３３抗体及びその使用
CN114181311B (zh) * 2021-12-20 2023-06-20 华东师范大学 一种全人源抗DLL3 scFv及其在CART细胞治疗中的应用
GB202204159D0 (en) * 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
WO2024059336A1 (en) * 2022-09-18 2024-03-21 Memorial Sloan Kettering Cancer Center Inhibition of protease-activated receptor 2 (par2) pathway for treatment and prevention of lymphedema

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716789A (en) 1993-07-26 1998-02-10 Cor Therapeutics, Inc. Method to determine ligands, agonist and antagonist of C140 receptor
DE69738539T2 (de) * 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US7888482B2 (en) * 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
WO2008086069A1 (en) * 2007-01-03 2008-07-17 The General Hospital Corporation Methods of treating itch
CL2008001887A1 (es) * 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
KR20090082619A (ko) 2008-01-28 2009-07-31 주식회사 알파크립텍 다프네틴을 함유하는 가려움증 또는 염증 개선용 화장료조성물
AR070911A1 (es) 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
CA2733041A1 (en) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Effectors of par-2 activation and their use in the modulation of inflammation
KR101360708B1 (ko) 2009-06-18 2014-02-07 (주)아모레퍼시픽 밤껍질 추출물을 포함하는 화장료 조성물
JP2012530699A (ja) 2009-06-18 2012-12-06 株式会社アモーレパシフィック 栗皮抽出物を含む健康食品又は薬学組成物
FR2947452B1 (fr) 2009-07-01 2012-04-20 Fabre Pierre Dermo Cosmetique L-serine et/ou l-asparagine et/ou l-valine pour prevenir et/ou au traiter des reactions inflammatoires de la peau.
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري

Also Published As

Publication number Publication date
PL2475684T3 (pl) 2017-04-28
IL218501A0 (en) 2012-07-31
US20110059095A1 (en) 2011-03-10
LT2475684T (lt) 2017-01-25
ZA201201730B (en) 2012-11-28
US8425907B2 (en) 2013-04-23
BR112012005338A2 (pt) 2016-11-22
US9028819B2 (en) 2015-05-12
KR101766701B1 (ko) 2017-08-09
JP2015227381A (ja) 2015-12-17
TW201121565A (en) 2011-07-01
HRP20170324T1 (hr) 2017-04-21
JP5832435B2 (ja) 2015-12-16
JP2013504577A (ja) 2013-02-07
US20120093824A1 (en) 2012-04-19
MY159551A (en) 2017-01-13
SMT201700102T1 (it) 2017-03-08
SMT201700102B (it) 2017-03-08
DK2475684T3 (en) 2017-03-06
AU2010292342C1 (en) 2015-08-27
TWI492757B (zh) 2015-07-21
CY1118714T1 (el) 2017-07-12
IL218501A (en) 2017-03-30
SG178976A1 (en) 2012-04-27
EP2475684A1 (en) 2012-07-18
WO2011031695A1 (en) 2011-03-17
US20140179903A1 (en) 2014-06-26
HK1166509A1 (en) 2012-11-02
SI2475684T1 (sl) 2017-03-31
AR078346A1 (es) 2011-11-02
UY32883A (es) 2011-03-31
AU2010292342B2 (en) 2015-04-30
US8101724B2 (en) 2012-01-24
HUE031725T2 (en) 2017-08-28
MX2012002927A (es) 2012-08-03
CN102574923A (zh) 2012-07-11
EP2475684B1 (en) 2016-11-30
KR20120059611A (ko) 2012-06-08
PT2475684T (pt) 2017-02-10
ES2609780T3 (es) 2017-04-24
NZ599204A (en) 2014-05-30
CA2773541A1 (en) 2011-03-17
AU2010292342A1 (en) 2012-05-03
CN102574923B (zh) 2016-12-07
JP6055055B2 (ja) 2016-12-27

Similar Documents

Publication Publication Date Title
JO3246B1 (ar) اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
EA201370081A1 (ru) Антитела к cd48 и их применение
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
JO3182B1 (ar) مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
UY31861A (es) Inmunoglobulina con dominio variable dual y usos de la misma
EP2575856A4 (en) INNOVATIVE DETECTION OF THERAPEUTIC, DIAGNOSTIC AND ANTIBODY COMPOSITIONS IN CONNECTION WITH PROTEIN FRAGMENTS OF GLUTAMINYL-TRNA SYNTHETASES
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201300239A1 (ru) Антитела к fap и способы их применения
UY32603A (es) Inmunoglobulina con dominio variable dual y usos de la misma
EA201290590A1 (ru) Модифицированные туберкулезные антигены
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
UY31862A (es) Inmunoglobulina con dominio variable dual y usos de la misma
EP2563912A4 (en) INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ASPARAGINYL TRNA SYNTHETASES
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
CR20110477A (es) Inhibidores de enzimas de proteina cinasa activadas por mitogeno p38
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
UA110051C2 (uk) Антитіло, яке зв'язує tgf-альфа та епірегулін
EP2582660A4 (en) NEW CATHEPSIN S PROTEASE INHIBITORS FOR THE TREATMENT OF e.g. AUTOIMMUNE DISEASES, ALLERGIES AND CHRONIC PAIN STATES
AR115423A2 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana